Research library
BPC-157 Research Overview: Proposed Angiogenic Pathways, Rodent Study Findings and the Absence of Human Data
- Compiled by:
- Peptide Pilots Scientific Content Team
- Reviewed by:
- Peptide Pilots Quality & Compliance review
- Last revised:
What does the published literature actually establish about BPC-157, and is there any human evidence?
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, described by its originating group as a fragment of a protein isolated from gastric juice. Essentially all published mechanistic findings come from rat models and cell studies from a small number of laboratories, and report effects on angiogenesis via VEGFR2/Akt/eNOS signalling, on nitric-oxide pathways and on growth-factor expression in injury models. There are no adequately powered, peer-reviewed randomised human trials of the peptide. The evidence base should therefore be described as preclinical and concentrated in a narrow set of research groups.
This page is an educational literature summary for laboratory professionals. It is not medical advice, not a description of product performance, and it does not describe or endorse human or veterinary use. Materials referenced are supplied for controlled laboratory research only.
What is BPC-157?
BPC-157 is a 15-residue peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) with no cysteine residues and no disulfide bonds, reported to be stable in human gastric juice for extended periods, which is unusual for a peptide of this size.
In laboratory work it is used in rodent models of tendon, muscle, gastrointestinal and vascular injury, and in endothelial cell assays examining tube formation and migration. A related arginate salt form appeared in earlier clinical-development records under the code PL 14736.
BPC-157 names and identifiers
Also referred to as: Body Protection Compound 157; PL 14736; PL-10; Bepecin; pentadecapeptide BPC 157
| Sequence (one-letter) | GEPPPGKPADDAGLV |
|---|---|
| Molecular formula | C62H98N16O22 |
| Average molecular weight | ≈1419.5 g/mol |
| CAS number | 137525-51-0 |
| Parent description | Reported partial sequence of body protection compound isolated from gastric juice |
| Registry records | Historic clinical-trial registrations under PL 14736 for inflammatory bowel indications |
BPC-157 research background
The peptide was described in the 1990s by a research group in Zagreb, Croatia, which reported isolating a protective compound from gastric juice and identifying an active 15-residue fragment.
Subsequent publications from that group and collaborators reported effects across a wide range of rat injury models, including tendon transection, muscle crush, gastric ulceration, colitis, fistula healing and vascular occlusion.
A separate development programme investigated an arginate salt form for inflammatory bowel disease, but no phase 3 results were published and development did not continue to approval. The core unresolved scientific question is whether the reported effects are reproducible in independent laboratories using blinded, preregistered designs.
Proposed BPC-157 mechanisms and pathways
Evidence is separated by study type. In-vitro and animal findings describe model systems and do not establish equivalent behaviour in humans.
BPC-157 in-vitro and cell-based evidence
- Endothelial cell studies report increased tube formation and migration, associated with upregulation of VEGFR2 and downstream Akt and eNOS phosphorylation.
- Reported activation of the FAK–paxillin pathway in fibroblast and tendon-cell cultures, associated with increased cell migration in scratch assays.
- The peptide has no confirmed high-affinity receptor; no crystal or cryo-EM structure of a BPC-157–receptor complex has been published, which is a major gap in the mechanistic account.
BPC-157 animal-model evidence
- Rat tendon and ligament transection models report faster biomechanical recovery and increased fibroblast outgrowth in treated animals.
- Gastrointestinal models report reduced lesion area in ethanol-, NSAID- and stress-induced ulceration protocols, with effects attributed in part to nitric-oxide system modulation.
- Vascular studies from the same research programme report collateral-vessel recruitment following venous or arterial occlusion, described as a 'bypassing' vascular response.
- Counter-regulatory findings are reported with L-NAME and L-arginine co-administration, used as evidence for nitric-oxide involvement.
Published BPC-157 human-study evidence
- No peer-reviewed randomised controlled trial reporting efficacy endpoints in humans has been published.
- Historic registrations for the arginate salt in inflammatory bowel disease exist, but published outcome data are limited to early-phase reports.
- Regulatory bodies in several jurisdictions have issued statements restricting compounding of the peptide, citing insufficient characterisation and safety data rather than positive findings of harm.
Published BPC-157 studies
| Study | Model / type | Research question | Main observation | Citation |
|---|---|---|---|---|
| Chang et al., tendon fibroblast study | Rat Achilles tendon fibroblasts in vitro | Does the peptide alter tendon-cell migration and adhesion signalling? | Increased outgrowth, survival and migration, with upregulated FAK–paxillin signalling. | Journal of Applied Physiology, 2011 |
| Hsieh et al., angiogenesis study | Endothelial cells and rodent ischaemia model | Is angiogenesis promoted, and through which receptor? | Increased VEGFR2 expression with Akt/eNOS activation; effects reduced by VEGFR2 blockade. | Journal of Molecular Medicine, 2017 |
| Sikiric et al., cytoprotection review | Narrative review of the originating group's rodent work | What is the reported breadth of activity across injury models? | Reports of protective effects across many organ systems; the review is authored by the originating laboratory and is not independent. | Current Pharmaceutical Design / related review series, 2020 |
| Independent replication landscape | Literature analysis | Have findings been reproduced outside the originating group? | The overwhelming majority of primary reports originate from, or are co-authored by, one research network; independent blinded replications are sparse. | US National Library of Medicine, 2026 |
Limitations of the BPC-157 evidence
- Publication concentration: most primary findings come from a single research network, and independent replication is limited. This is the most important caveat for anyone citing this literature.
- No identified receptor and no structural data, so the proposed mechanism is inferred from downstream pathway readouts rather than direct target engagement.
- Rodent injury models frequently used here have well-documented translation problems, and reported effect sizes are large relative to typical regenerative-medicine findings.
- Reporting quality varies: blinding, randomisation and sample-size justification are inconsistently described across the rodent literature.
- Pharmacokinetic characterisation is thin; distribution, metabolism and exposure data are limited relative to the breadth of claimed effects.
- No human efficacy or long-term safety data exist. Statements about human application found on commercial websites are not supported by the published record.
BPC-157 laboratory characteristics
Handling and analytical information reported in the literature and in supplier documentation. Values apply to laboratory materials and are not directions for any other use.
| Appearance | White lyophilised powder |
|---|---|
| Solubility | Freely soluble in water and in bacteriostatic or sterile aqueous buffers |
| Lyophilised storage | Commonly stored at −20 °C, desiccated |
| Reconstituted handling | Refrigerated and protected from light; short working periods are standard |
| Analytical testing | RP-HPLC purity and MS identity per lot; sequence confirmation by MS/MS where required |
| Stability considerations | Reported unusually stable in acidic media for a peptide of this length; no cysteines, so no disulfide scrambling |
Frequently asked BPC-157 research questions
What is the BPC-157 amino-acid sequence?
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV), a 15-residue peptide of approximately 1419.5 g/mol.
Is there a known BPC-157 receptor?
No. No high-affinity receptor has been identified and no structural data for a receptor complex have been published. Mechanistic claims rest on downstream pathway measurements.
Are there human clinical trials of BPC-157?
No peer-reviewed randomised controlled trials reporting efficacy endpoints have been published. Early registrations exist for an arginate salt form, without published phase 3 outcomes.
Why is independent replication emphasised on this page?
Because the majority of primary reports come from one research network. Concentrated authorship is a recognised marker of replication risk and should be stated whenever this literature is cited.
BPC-157 primary references
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival and cell migration. Journal of Applied Physiology. https://doi.org/10.1152/japplphysiol.00110.2011
- Hsieh MJ, Liu HT, Wang CN, et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. https://doi.org/10.1007/s00109-016-1488-y
- Sikiric P, Skrtic A, Gojkovic S, et al. (2020). Stable gastric pentadecapeptide BPC 157: cytoprotection and organoprotection. Current Pharmaceutical Design / related review series. https://pubmed.ncbi.nlm.nih.gov/?term=BPC+157+Sikiric+review
- PubMed literature index (2026). Current indexed literature for BPC 157. US National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/?term=BPC+157
Authorship and revision
Compiled from primary literature and public databases. Every factual statement on this page is traceable to a listed reference. Compiled by Peptide Pilots Scientific Content Team; documentation and compliance review by Peptide Pilots Quality & Compliance review. First published ; last revised . Pages are revised when the cited literature changes materially.
Catalogue reference
Peptide Pilots supplies BPC-157 as a laboratory reagent with per-lot RP-HPLC and mass-spectrometry documentation. Quantities, testing, packaging and fulfilment details are on the catalogue page.
Related catalogue products
Laboratory reagents supplied by Peptide Pilots from the Recovery, Tissue & Inflammation Research tier. Research use only; not for human or veterinary use.
